Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004104 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004104: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT00004104 is a Phase 2 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004104, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients who have stage III melanoma.
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL liposomal interleukin-2
- BIOLOGICAL polyvalent melanoma vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Phase | Phase 2 |
What the finished NCT00004104 record still lists
NCT00004104 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00004104 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004104 about?
NCT00004104 is a clinical study titled "Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma". RATIONALE: Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vacc...
What is the current status of trial NCT00004104?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-06.
What interventions are being tested in trial NCT00004104?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), liposomal interleukin-2 (BIOLOGICAL), polyvalent melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004104?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia